ChiCTR2600121726 版本V1.0 版本创建时间2026/04/02 08:57:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600121726 

最近更新日期:

Date of Last Refreshed on:

2026-04-02 08:57:23 

注册时间:

Date of Registration:

2026-04-02 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于机器学习算法的原发性肝癌患者肝切除术后肝衰竭在线可解释动态预测模型:一项回顾性队列研究

Public title:

Online interpretable dynamic prediction models for clinically significant posthepatectomy liver failure in patients with primary liver cancer based on machine learning algorithms: a retrospective cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于机器学习算法的肝癌背景下肝切除术后肝衰竭在线可解释动态预测模型:一项回顾性队列研究

Scientific title:

An online interpretable dynamic prediction model for liver failure after hepatectomy in the context of liver cancer based on machine learning algorithms: A retrospective cohort study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘召海 

研究负责人:

戴小明 

Applicant:

Liu Zhaohai 

Study leader:

Dai Xiaoming 

申请注册联系人电话:

Applicant telephone:

+86 193 3056 3048

研究负责人电话:

Study leader's
telephone:

+86 139 7475 2414

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

19330563048@163.com

研究负责人电子邮件:

Study leader's E-mail:

fydaixiaoming@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国湖南省衡阳市石鼓区船山大道69号

研究负责人通讯地址:

中国湖南省衡阳市石鼓区船山大道69号

Applicant address:

69 Chuanshan Avenue, Shigu District, Hengyang, Hunan, China

Study leader's address:

69 Chuanshan Avenue, Shigu District, Hengyang, Hunan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南华大学附属第一医院

Applicant's institution:

The First Affiliated Hospital, University of South China

研究负责人所在单位:

南华大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital, University of South China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025LL0515001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南华大学附属第一医院医学伦理审查委员会

Name of the ethic committee:

The First Affiliated Hospital of South China University Medical Ethics Review Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-15 00:00:00

伦理委员会联系人:

曾韵

Contact Name of the ethic committee:

Zeng Yun

伦理委员会联系地址:

中国湖南省衡阳市石鼓区船山路69号

Contact Address of the ethic committee:

69 ChuanShan Road, Shigu District, Hengyang, Hunan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 734857681

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南华大学附属第一医院

Primary sponsor:

The First Affiliated Hospital, University of South China

研究实施负责(组长)单位地址:

中国湖南省衡阳市石鼓区船山大道69号

Primary sponsor's address:

69 Chuanshan Avenue, Shigu District, Hengyang, Hunan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

衡阳

Country:

China

Province:

Hunan

City:

Hengyang

单位(医院):

南华大学附属第一医院

具体地址:

中国湖南省衡阳市石鼓区船山大道69号

Institution
hospital:

The First Affiliated Hospital, University of South China

Address:

69 Chuanshan Avenue, Shigu District, Hengyang, Hunan, China

经费或物资来源:

国家自然科学基金项目(82173899),湖南省自然科学基金项目(2022JJ70119)

Source(s) of funding:

National Natural Science Foundation of China (82173899), Natural Science Foundation of Hunan Province (2022JJ70119)

研究疾病:

原发性肝癌  

Target disease:

Primary liver cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

建立原发性肝癌患者肝切除术后肝衰竭的精确预测模型  

Objectives of Study:

To develop an accurate prediction model for liver failure after hepatectomy in patients with primary liver cancer

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄 18-85 岁; 2. 术前 Child-Pugh 分级 A 级或 B 级; 3. 术前无心肺、肾功能不全或肝性脑病

Inclusion criteria

1. Age 18-85 years old; 2. Preoperative Child-Pugh grade A or B; 3. There was no insufficiency of heart, lung or kidney function or hepatic encephalopathy before the operation

排除标准:

1. 术前胆道梗阻和 2. 两期肝切除术

Exclusion criteria:

1. preoperative biliary obstruction and 2. two-stage hepatectomy

研究实施时间:

Study execute time:

From 2025-03-31 00:00:00 To 2025-10-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-01 00:00:00 To 2025-10-30 00:00:00

干预措施:

Interventions:

组别:

PHLF组(根据国际肝外科研究组(ISGLS)的诊断标准,PHLF严重程度为B或C级),非PHLF组(PHLF严重程度为A级或无PHLF)

样本量:

285

Group:

PHLF group (according to the International Study Group of Liver Surgery (ISGLS) diagnostic criteria, PHLF severity was Grade B or C), Non-PHLF group (Grade A or no PHLF)

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

南华大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital, University of South China

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

精确召回曲线下的面积

指标类型:

主要指标

Outcome:

Area Under Precision Recall Curve (AUPRC)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

曲线下面积

指标类型:

次要指标

Outcome:

Area Under the Curve (AUC)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

精确度

指标类型:

次要指标

Outcome:

Precision

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

F1分数

指标类型:

次要指标

Outcome:

F1 score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

None

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

原始纸质版病历保存于病案室;自制表格录入被调查者资料,电子表格自备硬盘储存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original paper-based medical records are kept in the medical record room. Enter the information of the respondents in a self-made form. The electronic form should be stored on your own hard drive

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-02 08:57:23